Introduction
The clinical course of patients with follicular lymphoma (FL) is well known [1] [2] [3] [4] [5] [6] [7] [8] [9] . Histologic transformation to diffuse large B-cell lymphoma (DLCL; ILSG classification) [6] occurs in at least 15%-25% of patients with follicular lymphoma and confers a very poor prognosis. At autopsy, its incidence has been noted to be as high as 50% [10] . In most series the median survival is less than one year [10] [11] [12] [13] [14] [15] [16] .
In light of the poor outcome associated with transformation, and the success of high-dose therapy with autologous bone marrow transplantation (ABMT) in patients with a chemosensitive recurrence of de novo high-grade non-Hodgkin's lymphoma [17, 18] , highdose therapy was evaluated at St. Bartholomew's Hospital (SBH) in patients with a history of transformation of follicular lymphoma. The outcome of 27 consecutive patients treated at SBH from 1985-1996 is reported below.
Patients and methods

Patients
Patients with a history of transformation of follicular lymphoma (FL-t) at some point in the course of the disease were identified from a prospectively-compiled computer database of all patients referred (either at presentation or at recurrence) to the ICRF Medical Oncology Unit at SBH from 1985-1996. The following patients were included ( Figure 1 ): patients with FL at presentation and transformation at recurrence; patients with FL-t or DLCL (I.L.S.G. Classification) [6] at presentation and FL at recurrence; and patients with FL at presentation, FL-t at progression, and a subsequent recurrence of FL. Fourteen of 27 patients in this report were included in an earlier report from the EBMT registry [19] .
All biopsy specimens were reviewed and the diagnosis confirmed at SBH by Dr. A. G. Stansfeld, or AJN. The medical records of patients were reviewed, and outcomes updated to 1997. Table 1 . Characteristics of patients in group 1 at the time of high-dose therapy (n = 19). Patients were eligible for high-dose therapy if they were aged less than 60 years, were medically fit, and were in either complete remission or a 'minimal disease state' after treatment for recurrent lymphoma. The latter was defined as residual lymphadenopathy of less than 2 cm diameter at three or fewer sites, and/or less than 20% bone marrow infiltration on bilateral bone marrow biopsies.
Group 1
A total of 56 patients with histologic transformation from FL to FL-t were identified. Thirty-seven of 56 were considered ineligible for highdose therapy for the following reasons: 18 were aged greater than 60 years; in 16 an adequate response to chemotherapy was not achieved, or high-dose therapy was considered inappropriate in the context of rapidly progressive disease; and sufficient cells to support high-dose therapy could not be obtained in two patients. One patient was medically unfit to receive high-dose therapy despite achieving a response to salvage chemotherapy for FL-t.
Group 1: Patients who received high-dose therapy
Therefore, 19 of 56 patients (34%) received high-dose therapy as consolidation of complete or almost complete remission of transformed follicular lymphoma (50% of patients aged < 60 years). Their clinical characteristics at the time of high-dose therapy are shown in Table 1 , and the extent of disease at transformation is noted in Table 2 . In nine of 19, FL-t was the first manifestation of recurrent lymphoma. All but one patient had received previous chemotherapy for follicular lymphoma, and therefore received high-dose therapy in second or subsequent remission. The exception was a 39-year-old patient who was managed expectantly at presentation of FL, and received treatment following transformation one year later. This patient received highdose therapy in first remission.
The median time from diagnosis of histologic transformation to high-dose therapy was six months (range three to 12 months). All 19 patients received salvage chemotherapy at the time of transformation. Eighteen of 19 were treated with a doxorubicin-containing regimen; two of 18 received further treatment with etoposide and intermediate dose cytosine arabinoside [20] . The remaining patient received etoposide and cytosine arabinoside alone.
At the time of high-dose therapy, four patients were in complete remission (CR), the remaining 15 were in a 'minimal disease state'. Two of the latter had residual BM infiltration, and 13 had evidence of residual lymph node (LN) involvement, or small residual abnormalities of unknown significance on CT scanning. One patient in remission of FL-t after seven cycles of CHOP-M chemotherapy [21] developed a biopsy-proven recurrence with FL at the time of the planned high-dose consolidation. She was then treated into remission with fludarabine, but suffered a further localised recurrence with FL-t. The patient therefore received high-dose therapy with a radiation boost to the involved site.
Group 1: Patients who did not receive high-dose therapy
Twenty-eight of the 37 patients with FL-t who did not receive highdose consolidation have died (22 progressive lymphoma; four treatment-related deaths; two lung cancer). One is lost to follow-up with refractory and progressive transformed lymphoma, seven have had a recurrence of lymphoma requiring further therapy (six FL-t; one FL), and one is being managed expectantly for asymptomatic FL. Eighteen of 37 patients were not considered for high-dose therapy because they were aged > 60 years: 13 of 18 have died (eight progressive lymphoma; three treatment-related deaths; two lung cancer), four have required further therapy for FL-t, and one patient is being managed expectantly for asymptomatic FL.
Group 2: Patients who received high-dose therapy
Eight additional patients with a prior history of DLCL or of FL-t also received high-dose therapy as consolidation of remission, after an intervening recurrence at which the histology was follicular lymphoma (Figure 1 ). Five developed recurrent follicular lymphoma after treatment forde novo DLCL or FL-t, and three had a recurrence with FL after a chemotherapy-induced remission of FL-t, having presented originally with FL. The clinical characteristics of these eight patients are shown in Table 3 . The median time from histologic transformation to high-dose therapy was 2.3 years, reflecting the fact that all eight of these patients were treated after a recurrence of FL.
Group 2: Patients who did not receive high-dose therapy
Three further patients with a history of de novo DLCL and relapse with follicular lymphoma were identified. One did not achieve a stable remission of FL, and died of infectious complications after receiving fludarabine. The remaining two were aged > 65 years at the time of the transformation: one is alive with FL, and the other has died of a subsequent recurrence of DLCL.
Treatment
Myeloablative therapy comprised high-dose cyclophosphamide and mesna (Cyclo: 60 mg/kg x 2 days), and fractionated total body irradiation (TBI: 200 cGy x 6). Autologous haematopoietic progenitor cells were infused the day following the completion of TBI. Autologous BM was used to support the treatment in 23 patients and PBPC in four. The BM mononuclear cell (MNC) fraction was treated in vitro with one or four anti-B cell antibodies and baby rabbit complement as previously described [22] . PBPC's were mobilised with doxorubicin. etoposide and G-CSF, and harvested by leukapheresis [23] . A mini- Abbreviations: DLCL -diffuse large B-cell lymphoma; FL -follicular lymphoma; FL-t -transformed follicular lymphoma; TRM -transplant-related mortality; MDS -myelodysplasia.
mum number of 1.5 x 10 /kg MNC's was deemed necessary, in the presence of a minimum of 1 x 10 6 /kg CD34+ cells in order to proceed with the high-dose therapy. G-CSF was not used routinely after reinfusion of BM or PBPC.
Follow-up
Patients were restaged three months after high-dose therapy, and then annually with clinical review, CT scans of the chest, abdomen and pelvis, and unilateral bone marrow trephine biopsy and aspirate. so ., 4 6 TIME (YEARS) Figure 3 . Disease-free survival from high-dose therapy: All patients.
Statistical analysis
Survival from histologic transformation was measured from the date of biopsy-proven transformation, and survival from high-dose therapy was measured from the date of re-infusion of autologous BM or PBPC. Survival curves were calculated according to the method of KaplanMeier [24] . Survival between groups was compared for statistical significance using the log rank test.
Results
Outcome of all patients
At a median follow-up of 2.4 years, 17 of 27 patients are alive, and 14 remain in remission. The median survival is 8.5 years. There were two 'early' and two 'late' treatmentrelated deaths; the remaining patients have died of recurrent lymphoma. The overall survival and disease-free survival are shown in Figures 2 and 3 , respectively.
Group 1
With a median follow-up from re-infusion of 2.4 years, 10 of 19 patients (52%) are alive and remain free of progression. The median survival from high-dose therapy is 4.4 years ( Figure 4) ; three patients are in remission at greater than four years' follow-up ( Figure 5 ). One patient died of respiratory failure one month after re-infusion. Eight patients have developed recurrent lymphoma. Six of eight patients underwent re-biopsy at recurrence; two patients had obvious progression at sites of previous transformed lymphoma at one and two months after high-dose therapy, and re-biopsy was not performed. In five of six, biopsy documented recurrent FL-t; two of five are alive and in remission after further chemotherapy at 1.5 years and 4.2 years following recur-rence. In one patient, histology at recurrence showed follicular lymphoma, and this patient died 2.5 years later of progressive disease.
A total of six of 19 patients achieved a CR at some point after histologic transformation: four of six patients after salvage chemotherapy, and two further patients at restaging after high-dose therapy. Their survival was not significantly different from that of patients in whom CR was not achieved.
Group 2
The individual outcome of these eight patients is also shown in Table 3 . There has been only one recurrence of NHL; that patient is alive without therapy after an asymptomatic, surveillance recurrence of FL in the BM at 3.75 years.
Toxicity
Toxicity of the high-dose treatment has been considered for all 27 patients together. There were two 'early' treatment-related deaths (less than three months from rere-infusion) from respiratory failure. Two patients have developed fatal secondary myelodysplasia (MDS) at 2.8 and 8.5 years after high-dose therapy respectively; both of these were from group 2 ( Table 2) .
Data on time to engraftment are available for 22 of 23 patients receiving BM as haematopoetic support; the remaining patient died prior to engraftment. The median time to recovery of a neutrophil count > 0.5 x 10 9 /l was 26 days (range 13-55), and to an unsupported platelet count of > 20 x 1O 9 /1, 30 days (range .
Discussion
These results show that consolidation therapy with high-dose cyclophosphamide and TBI and autologous haematopoietic progenitor cell support is feasible, and effective for a proportion of patients with transformed follicular lymphoma. 19 of 38 (50%) younger patients (aged <60 years) considered for high-dose therapy actually received the treatment; 10 of 19 (53%) remain in remission. Superficially, this is similar to the experience with ABMT in recurrent high-grade NHL [18] .
This was not a randomised study, so that comparison can only be made with reports prior to the introduction of high-dose therapy [5, [11] [12] [13] [14] [15] . In this report, more than one half of the patients are alive and in remission after high-dose consolidation. While only younger patients achieving a 'minimal disease state' were selected for this therapy, the results are at least encouraging.
Previous reports of high-dose therapy following histologic transformation are somewhat contradictory. In an early report from the University of Nebraska, seven of 10 patients who received high-dose therapy with ABMT after transformation died within approximately three months from transplant-related mortality (TRM), and two died of recurrent lymphoma [25] . Only one patient was reported to be in remission at follow-up. However, only five of 10 patients had chemotherapyresponsive disease, and most had bulky disease at the time of high-dose therapy. In contrast, 12 of 18 patients treated at the Dana-Farber Cancer Institute in a 'minimal disease state' after histologic transformation with high-dose cyclophosphamide, TBI and B-cell-'purged' autologous BM, remain in CR [26] . The median disease-free survival was greater than three years. In a report from three centres in France, six of 16 patients who received high-dose treatment with PBPC support in remission of FL-t remain alive and free of disease [27] . The differences in outcome between these series probably relate to patient selection.
In a report from the EBMT registry, 48 patients with histological transformation of follicular lymphoma underwent ABMT, with a 50% and 33% overall and progression-free survival (PFS) respectively at five years [19] . The median PFS was 14 months. Of note, the TRM was 8.3%. The benefit was most evident for patients with chemosensitive disease, and for those in whom CR was achieved.
A recent report of 74 patients in long-term follow-up of histologic transformation from Stanford, demonstrated a median survival of 1.8 years. However, patients with limited stage disease and those in whom CR was achieved following treatment for transformation (n = 30) had a long median survival (6.75 years) [28] . It may be that such 'good risk' patients can be observed in remission of FL-t. Because of the TRM and the risk of secondary MDS associated with high-dose therapy, more data are needed to determine the patients for whom a conservative approach like this may be appropriate. The fact that patients achieving CR in the present series did not have a superior outcome probably reflects selection of patients already achieving a 'minimal disease state'.
In this study, eight patients with a previous history of either de novo high-grade lymphoma or of de novo FL-t, with a subsequent recurrence of FL, also received highdose therapy. These patients may have a more indolent course, and have therefore been considered separately.
Only 1 patient has had a recurrence of lymphoma, and has been observed with asymptomatic FL. However, two patients from this group have developed secondary MDS. Because of this, patients being considered for high-dose therapy at SBH are screened for morphological or cytogenetic evidence of myelodysplasia prior to proceeding to high-dose therapy.
Eighteen of the cohort of patients seen at SBH with FL-t (group 1) were not considered for high-dose therapy because of their age; with the exception of two patients who died of lung cancer in remission of FL-t, all have had a recurrence of lymphoma in follow-up. With the lower transplant-related mortality associated with the use of PBPC, due mostly to the more rapid haematologic recovery, it may be possible to deliver this treatment safely to older patients [23, 27] .
Repeat biopsy should be considered for all patients with recurrent lymphoma after high-dose therapy; therapy would obviously be guided by histology in this circumstance. While most recurrences in this series were with FL-t, recurrences with FL were seen, and have been previously reported in remission of FL-t and after high-dose consolidation of histologic transformation [27, 28] .
In conclusion, intensive therapy followed by highdose cyclophosphamide and TBI with autologous haematopoietic support after histologic transformation may alter the natural history of this disease, and is appropriate for younger patients with chemosensitive disease.
